

NEXT SCIENCE[®]

Quarter ending 30 June 2022 Investor Presentation

25 July 2022

Approved by the Board of Next Science

Disclaimer

This presentation has been prepared by Next Science Limited (**Company**) and is provided for general information purposes only. It is not a product disclosure statement, pathfinder document or any other disclosure document for the purposes of the *Corporations Act 2001* (Cth) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission (**ASIC**). It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company. This presentation should not be considered an offer or an invitation to acquire or sell, or a solicitation to invest in or refrain from investing in, new shares in the Company or any other financial products.

This document has been prepared based on information available as at the date of this presentation. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant or which a prospective investor may require in evaluations for a possible investment in the Company. It should be read in conjunction with the Company's periodic and continuous disclosure announcements which are available at www.nextscience.com and www.asx.com.au. The recipient acknowledges that circumstances may change and that this presentation may become outdated as a result. This presentation and the information in it are subject to change without notice. The Company is not obliged to update this presentation.

The information contained in this presentation does not constitute investment, legal, tax, accounting or financial product advice nor any recommendation to acquire securities in the Company. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (**Forward Statements**). Forward Statements can generally be identified by the use of forward looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance or outlook on future revenues, distributions or financial position and performance or return or growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (together, the **Next Science Parties**) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in \$USD unless stated otherwise.

An investment in Company shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director or partner of, or in the employment of, the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the Next Science Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information. To the maximum extent permitted by law, the Next Science Parties: exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

Q2 2022 Highlights – strategy to expand portfolio coverage and market awareness are accelerating product sales growth, up 99% vs pcp

- Product sales growth in Q2 2022, 99% increase on pcp and 70% on prior quarter
- 1st shipments to Zimmer of XPERIENCE™ in June 2022
- XPERIENCE™ launched in New Zealand with dedicated Distributor
- Appointed XPERIENCE™ dedicated Distributor for Australia with first shipment expected in Q3 2022.
- Distributor appointed for BlastX™ in Australia and New Zealand with expected Q3 2022 launch
- Expanded New Zealand surgical distribution to include Surg X™ with first shipments expected in Q3 2022.

99% Q2 2022 Product sales growth on pcp


Increased US XPERIENCE™ customer base to 142 Hospitals (+19% on Q1 2022) and 258 Surgeons (+23% on Q1 2022)*

Zimmer commenced controlled rollout of XPERIENCE™ in July 2022

First clinical XPERIENCE™ case study results to be published in Q3 2022 – 900 Cases Zero Infections

*From 1 July 2022, XPERIENCE™ is being sold through multiple distributors, accordingly, hospital and surgeon data will no longer be available.

Product sales Q2 2022 +99% vs pcp, 70% on Q1 2022



	Q2 2021 (audited)	Q1 2022 (unaudited)	Q2 2022 (unaudited)
Product Revenue	\$1.6	\$1.9	\$3.3
Other Revenue *	\$0.0	\$0.1	\$0.1
Total Revenue	\$1.7	\$2.02	\$3.39

*other revenue includes the release of milestone payments, royalties and license fees

- Product sales increased 99% on pcp, showing underlying market adoption – excludes other revenue*. 70% growth on prior quarter
- Product sales contributions in Q2 2022 from Bactisure™, XPERIENCE™, BLAST X™, TridentX™ and SURGX™
- The majority of sales in Q2 2022 were generated from the US with first initial sales from New Zealand

Next Science's Xbio product platform– US\$22B total addressable market

Treating chronic wounds:

8.2 million patients in the US¹
Total addressable market \$11B

Causes deaths in 27.7% of patients within a 2 year period.²

Cost to US healthcare system to treat >\$50B pa²

Approved products are reimbursed by CMS
(Medicare/Medicaid) and main insurers

NXS 2022 focus:

- Veterans Affairs' hospitals (171 medical centres and 1,121 outpatient clinics)
- Chronic wound clinics in commercial hospitals
- (>1800 Centres)
- Private Podiatry offices (DFUs) (>10,382 offices)

Preventing surgical site infection (SSI):

Total market 110 million surgical procedures pa¹
2 million SSIs occurring per year in the US¹
SSI causes 90,000 deaths pa

Total addressable market \$11B

Cost to US healthcare system to treat \$25-40B pa¹,
increased 36% in the past decade¹


Preventative technologies covered in 'Episode of Care' costs paid by insurance companies or by CMS (Medicare/Medicaid)

NXS current focus:

- >7M orthopaedic procedures pa
- >1.2M plastic surgeries pa

Activity Update - Good progress expanding awareness and adoption

- YTD 2022 US XPERIENCE™ adoption has increased to 258 surgeons (~1% of US orthopaedic surgeons*) in 142 US hospitals*
- Two month rollout of XPERIENCE™ commenced in July through Zimmer's exclusive hip & knee field force of sales agents to provide increased access to the US orthopaedic market
- XPERIENCE™ sales commenced in New Zealand in June
- Successfully resolved Irrimax dispute (July 2022)
- Search underway for new US based CEO, as announced at the AGM
- Further expansion of direct sales team (+5)
- First shipment of TridentX™ wound wash to Convatec
- Expanded "Irrigation" publications to 6



*From 1 July 2022, XPERIENCE™ is being sold through multiple distributors, accordingly, hospital and surgeon data will no longer be available.

XPERIENCE™ – executing growth strategy to accelerate adoption

XPERIENCE™

2021

Create awareness and key opinion leader base

- ✓ Set up reference sites with key opinion leaders
- ✓ Build on Area sales managers with Account managers
- ✓ Establish key studies
- ✓ Create awareness through marketing campaigns

2022-2023

Drive adoption and grow evidence

- ✓ Increase penetration across accounts growing the Account manager teams
- ✓ Increased market access through distribution with Zimmer Hip & Knee sales team (H2)
- ✓ Increase market coverage with White Label products for designated market segments
- ✓ Expansion to ANZ through distributors
- ✓ Support Investigator studies in all key product applications
- Complete and publish inflammation in joint study, impact on bone cement adhesion study ('pull out study'), bioburden studies and retrospective hip & knee case series

2023 onwards

Mass market adoption – becoming the standard of care

- Strategy to become standard of care by 2026:
- Complete and publish key primary joint study – Total addressable market US\$0.6B in USA
 - Complete and publish key colorectal study, broadening product indications & expanding addressable market to US\$11B in USA
 - Continued growth of market coverage through direct and indirect representation

Develop model for expansion in US Wound Care market

Wound Care

2021

Re- establish existing customer base

- ✓ Get Veterans Affairs and Department of Defence hospitals back to ordering from coast to coast
- ✓ Establish deeper utilisation within VA and DoD accounts
- ✓ Utilise direct representation in Kaiser network to become standard of care

2022-2023

Open new segments and grow evidence


- Trial in home health
- Widespread survey of use of BlastX with standard of care options
- Lean into health economics study to support wide utilization

2023 onwards

Expand utilization

- Combination application with other wound products
- Seek to improve reimbursement for products in the market
- Publish data

1H 2022 Cash waterfall – well funded to execute growth strategy



2022 Launch calendar – more products, more markets, accelerating sales

- ✓ Q2 TridentX™ (TorrentX) – US
 - ✓ 2H XPERIENCE™ with Zimmer in the US
-



- ✓ Q2 XPERIENCE™ in New Zealand
- ✓ 2H SurgX™ in New Zealand
- ✓ 2H XPERIENCE™ in Australia
- ✓ 2H BlastX™ Australia & New Zealand



Summary: Positive 2H outlook with new distribution partnerships, product launches and expanded territories

Executing strategy to accelerate market awareness and adoption of Next Science's Xbio platform – market leading infection prevention and treatment technologies

- ✓ Q2 2022 product sales growth(unaudited) , +99% on pcp. Contributions from 6 products in US market, 11 regulatory approvals, 44 patents
- ✓ Signed multiple new distribution agreements in the Quarter to expand commercial reach and support for clinicians
- ✓ Additional commercial launches already under way in the US and other markets, to complement further growth in 2H:
 - ✓ Zimmer launch of XPERIENCE™ in the US
 - ✓ New Zealand launch of XPERIENCE™ and SurgX™
 - ✓ US Launch of TridentX™ Wound Wash
 - ✓ Australia launch of XPERIENCE™ with focussed dedicated Australian distributor Novus Surgical
 - ✓ Australia and New Zealand launch of BlastX™ with Oraderm
- Further independent research publications on positive results with Bactisure™, XPERIENCE™ and BlastX™ supporting commercial growth strategy

NEXT SCIENCE[®]

Appendix

Next Science purpose – healing people – saving lives

Platform technologies that protect from biofilms and chronic infections

Next Science offers unique and significant benefits to health systems and patients

Reduce hospital
acquired
infections and
improved surgery
success rates



Better patient
outcomes – lower
surgical site
infection rate




Treatments that
don't increase
antibiotic
resistance



Allows hospitals
to reduce overall
cost of
complications
and readmissions

Next Science technologies meet the triple aim: better patient outcomes, improving patient health, and reducing cost of healthcare

Executing our growth strategy: building market acceptance and growing revenues while creating new standards of care



Prevention products portfolio to serve the US Market

XPERIENCE™

Indication: Prevention of surgical site infection

Cost: Surgical site infection in the US >\$3.6B



US Market: 45 million patients p.a.

SurgX™

Indication: Prevention of infection on a surgical closure

Cost: Surgical site infection in the US >\$3.6B



US Market: 45 million patients p.a.

TridentX™

Indication: Site preparation for tissue graft in Chronic wounds

Cost: Treatment of chronic wounds in the US estimated at \$28-\$96B



US Market: 8 million patients p.a.

Dispersing biofilms, reducing infection, promoting healing

Bactisure™ Surgical Lavage

Indication: Elimination of surgical site infection



US Market: 250,000 patients p.a.

BlastX™ Antimicrobial Wound Gel

Indication: Treatment of chronic wounds, foot & leg ulcers, bedsores, pressure ulcers



US Market: Cost of \$28-\$31B and 8 million patients p.a.

Acne Treatments

Indication: Treatment of acne and breakouts



Market: Currently offered in Australia

Recent Publications

- Bashyal & James: [https://www.arthroplastyjournal.org/article/S0883-5403\(22\)00062-6/fulltext](https://www.arthroplastyjournal.org/article/S0883-5403(22)00062-6/fulltext)
- Knapp, Chen, Scuder, Mont: October 2021 [Surgical Technology International](#) 39 DOI: [10.52198/21.STI.39.OS1514](https://doi.org/10.52198/21.STI.39.OS1514)
- [Vickey, Hu, Parvan, Deva](#): <https://pubmed.ncbi.nlm.nih.gov/35629656/>
- [Christopher, Tran, Vernon, Spangehl](#): <https://pubmed.ncbi.nlm.nih.gov/34740788/>
- [O'Donnell, James, Seyler et al](#) : <https://pubmed.ncbi.nlm.nih.gov/33934664/>
- [Plate, Zuskov, Seyler](#):
https://journals.lww.com/jaaos/Citation/2021/12010/Use_of_Adjunct_Antiseptic_Agents_in_Periprosthetic.3.aspx
- [O'Donnell, Jams, Seyler et al](#): <https://journals.healio.com/doi/full/10.3928/01477447-20211227-05>

Investigator research table – first case study reports due 2H 2022

Indication	Product	Study Size	Structure	Status	Sites
Impact on Bone Cement Adhesion	XPERIENCE™	Invitro & Animal study	Fee for Service	First data strong, more tests underway	Contracting with UNSW Surgical and Orthopaedic Research Lab (Dr B Walsh)
Post Operative Inflammation in joints	XPERIENCE™	30	Investigator sponsored research. Imaging Technology provided by Next Science	Patients being recruited	Dr A Wickline Utica (New York)
Post Operative Infection	XPERIENCE™	300	Investigator Case Series	Retrospective of first 300 completed XPERIENCE™ joint surgeries	MUSC, South Carolina
Post Operative Infection	XPERIENCE™	900	Investigator Case Series	Retrospective of first 900 completed XPERIENCE™ joint surgeries	Jack Hughston Memorial Hospital Columbus, Georgia
Surgical Site Infection in Primary Joint Replacement in complex patients	XPERIENCE™	1,200	Investigator Research Study (Product Donated)	Patients being recruited Expected completion 2023	Dr Scuderi Northwell Group Lennox Hill + 6 Northwell sites
DAIR Study on acutely infected joints	XPERIENCE™ BACTISURE™	192	NXS sponsored study, product donated,	Protocol finalised. Contracts under development for each site Expected completion 2023	Dr Jon Minter Northside Hospital Atlanta, UAB Alabama, NE Baptist, Northwell Group New York and Delaware, FOI Tampa, Hope Orthopaedics Salem, Scripps, 21 Surgeon Participants

Larger clinical studies to establish standard of care

Indication	Product	Study Size	Structure	Status	Expected Reporting date	Sites
Compound Tibial Fracture Infection (Pilot Study)	XPERIENCE TM	30	Investigator Research Study (Product Donated)	Patients being recruited	December 2022	Hughston Memorial Clinic, University of Alabama
Bioburden In Vivo Study	XPERIENCE TM	30	Investigator sponsored research	IRB under review,	Q4 2022	Dr Bashyal (Chicago)
Surgical Site infection in Primary Joints	XPERIENCE TM	7600	Investigator Research Study, Product donated	Randomised Controlled study over 5 sites in Canada PI Dr Beale, Dr Garceau University of Ottawa	Q4 2024	Site applying to the Canadian government for approval to commence the clinical trial
BioBurden In Vivo Study	XPERIENCE TM	172	Investigator sponsored research	Contracts in development	Q4 2023	Mayo Clinic
Surgical Site Infection in Colorectal surgery	XPERIENCE TM	560	Investigational Device Exemption (IDE) for expanded indications	Randomised Control study 3 sites. Houston VA, Memorial Herman Hospital,	2025	Pre-clinical animal study required by the FDA
Animal Study on effectiveness	XPERIENCE TM	Animal Study	Investigator Sponsored Research	Contracts under review	Q1 2023	Cleveland Clinic

References

1. K Sen: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389759/>
2. https://www.researchgate.net/publication/51199135_High_mortality_in_patients_with_chronic_wounds
3. <https://www.definitivehc.com/blog/how-many-orthopedic-surgeons-in-us#:~:text=According%20to%20Definitive%20Healthcare's%20PhysicianView,hand%20surgery%2C%20and%20joint%20replacement>